|
|
|
|
|
Alfuzosin
drug data and news
Alfuzosin drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Alfuzosin | ||
| Brand Names/Synonyms | Uroxatral; Xatral | ||
| Indication | For the treatment of the signs and symptoms of benign prostatic hyperplasia | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Alfuzosin is an alpha-adrenergic blocking agent used to treat hypertension and benign prostatic hyperplasia. Accordingly, Alfuzosin is a selective inhibitor of the alpha1 subtype of alpha adrenergic receptors. In the human prostate, Alfuzosin antagonizes phenylephrine (alpha1 agonist)-induced contractions, in vitro, and binds with high affinity to the alpha1c adrenoceptor, which is thought to be the predominant functional type in the prostate. Studies in normal human subjects have shown that Alfuzosin competitively antagonized the pressor effects of phenylephrine (an alpha1 agonist) and the systolic pressor effect of norepinephrine. The antihypertensive effect of Alfuzosin results from a decrease in systemic vascular resistance and the parent compound Alfuzosin is primarily responsible for the antihypertensive activity. | ||
| Mechanism Of Action | Alfuzosin acts by inhibiting the postsynaptic alpha(1)-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation. | ||
| Alfuzosin News (When available) |
Recovery Of Abnormal Ejaculation By Intermittent Tamsulosin ... Feb 28, 2006 | ||
| Dosage Forms | TABLET (EXTENDED-RELEASE) | ||
| Drug_Category | Antihypertensive Agents; Unclassified Therapeutic Agents (92:00.00); ATC:G04CA01 | ||
| Absorption | Absorption is 50% lower under fasting conditions | ||
| Interactions | Interactions for Alfuzosin: Drug-Drug Interactions: The pharmacokinetic and pharmacodynamic interactions between Alfuzosin and other alpha-blockers have not been determined. However, interactions may be expected, and Alfuzosin should NOT be used in combination with other alpha-blockers. | ||
| Toxicity | side effects are dizziness (due to postural hypotension), upper respiratory tract infection, headache, and fatigue | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)-methyl-amino]propyl]tetrahydrofuran-2-carboxamide | ||
| Chemical Formula | C19H27N5O4 | ||
| Molecular Weight | 389.449 g/mol | ||
| Smiles String | CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC | ||
| Melting Point | Not Available | ||
| Water Solubility | Not Available | ||
| State | Solid | ||
| LogP/Hphobicity | 1.604 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Hepatic | ||
| Half Life | 10 hours | ||
| Protein Binding [%] | 82%-90% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Alfuzosin.html http://www.rxlist.com/cgi/generic3/uroxatral.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00490 | ||
| CAS Registry Number | 81403-80-7 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | SID:63198 | ||
| PharmGKB ID | PA10357 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2245565 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |